Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Locally Advanced Bladder Urothelial Carcinoma: early-phase trial registry
1 of 9 indexed Locally Advanced Bladder Urothelial Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 1 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Locally Advanced Bladder Urothelial Carcinoma: 9 US clinical trials tracked, 1 recruiting.
Locally Advanced Bladder Urothelial Carcinoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition locally-advanced-bladder-urothelial-carcinoma
OPEN 1 | RECR 11% | LATE 3 | EARLY 6 | RANK #1916 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Alcohol Use Disorders (11% recruiting · 9 trials)
Locally Advanced Bladder Urothelial Carcinoma lists 1 open slots (11% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Locally Advanced Bladder Urothelial Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Locally Advanced Bladder Urothelial Carcinoma is recruiting below its size-band peers.
1 of 9 indexed trials (11.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Locally Advanced Bladder Urothelial Carcinoma research.
National Cancer Institute (NCI) accounts for 4 of 9 trials (44.4%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Locally Advanced Bladder Urothelial Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 24 among the 9 trials that report a genuine target (sentinel values excluded). 8 of those (88.9%) plan for fewer than 100 participants.
-
Locally Advanced Bladder Urothelial Carcinoma research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
NCT06764095
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
National Cancer Institute (NCI)
NCT03244384
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
National Cancer Institute (NCI)
NCT03237780
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
NCT04940299
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
National Cancer Institute (NCI)
NCT04963153
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
National Cancer Institute (NCI)
NCT03047213
ARID1A and/or KDM6A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
NCT04953104
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
Emory University
NCT04848519
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
Alliance for Clinical Trials in Oncology
NCT04637594
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Locally Advanced Bladder Urothelial Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Locally Advanced Bladder Urothelial Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Locally Advanced Bladder Urothelial Carcinoma page
9 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Locally Advanced Bladder Urothelial Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Locally Advanced Bladder Urothelial Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Locally Advanced Bladder Urothelial Carcinoma condition card totals 9 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.